Stock PULMATRIX INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Pulmatrix Inc Nasdaq

Equities

US74584P1030

Biotechnology & Medical Research

Business Summary

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Class of Inhaled Therapeutic Products
100.0 %
6 100.0 % 7 100.0 % +20.21%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
6 100.0 % 7 100.0 % +20.21%

Managers

Managers TitleAgeSince
Teofilo Raad CEO
 Chief Executive Officer 54 17-05-02
Peter Ludlum DFI
 Director of Finance/CFO 68 22-04-17
Aidan Curran CTO
 Chief Tech/Sci/R&D Officer - 14-12-31

Members of the board

Members of the board TitleAgeSince
Richard Batycky BRD
 Director/Board Member 56 19-10-31
Christopher Cabell BRD
 Director/Board Member 54 20-06-22
Todd Bazemore BRD
 Director/Board Member 53 20-09-30
Anand Varadan BRD
 Director/Board Member 57 21-07-25
Teofilo Raad CEO
 Chief Executive Officer 54 17-05-02
Michael Higgins CHM
 Chairman 61 15-06-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,652,285 3,652,260 ( 100.00 %) 0 100.00 %

Shareholders

NameEquities%Valuation
Renaissance Technologies LLC
3.212 %
117,321 3.212 % 205 312 $
BlackRock Institutional Trust Co. NA
1.503 %
54,900 1.503 % 96 075 $
Sabby Management LLC
1.484 %
54,188 1.484 % 94 829 $
Vanguard Group, Inc. (Subfiler)
0.9605 %
35,082 0.9605 % 61 394 $
Geode Capital Management LLC
0.6752 %
24,660 0.6752 % 43 155 $
STATE STREET CORPORATION
0.3818 %
13,945 0.3818 % 24 404 $
Tower Research Capital LLC
0.0977 %
3,570 0.0977 % 6 248 $
Securities America Advisors, Inc.
0.007557 %
276 0.007557 % 483 $
UBS Financial Services, Inc.
0.004518 %
165 0.004518 % 289 $
Wells Fargo Bank NA
0.000767 %
28 0.000767 % 49 $

Company contact information

Pulmatrix, Inc.

36 Crosby Drive Suite 100

01730, Bedford

+781 357 2333

http://www.pulmatrix.com
address Pulmatrix Inc

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.96% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.34% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.59% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.61% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.43% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.79% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PULM Stock
  4. Stock
  5. Company Pulmatrix Inc